Anjali Budhathoki, M.D
NPI 1548558166 · Southeast · Owned by Dr. James Park
Discover current approach to tx selection patterns between T-DXd + P and existing regimens for 1L HER2+ a/mBC
Driving dimension: Tx selection patterns between T-DXd + P and existing regimens for 1L HER2+ a/mBC
Impact context
An emerging voice with growing visibility. Lighter-touch engagement; identify areas of scientific curiosity and build foundational rapport.
Knowledge context
Limited evidence exposure in this area. Lead with core clinical data and foundational context, keeping it clear and grounded in patient relevance. Let their questions set the pace for going deeper.
Suggested materials
- DESTINY-Breast09 (D967UC00001) Fam-Trastuzumab Deruxtecan-nxki (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-Positive First Line Metastatic Breast Cancer (Reactive Slide Deck; MED-US-TRAS-00436): Slides 16–37
- DESTINY-Breast09 Medical Q&A (FAQ Document; MED-US-TRAS-00437): All questions from DESTINY-Breast09 Efficacy Results, DESTINY-Breast09 Key Subgroup Analysis Results
- Discussion Guide: T-DXd+ P in 1L HER2-Positive mBC (Reactive Slide Deck; MED-US-TRAS-00412): Slides 9–14, 26–36, 42–47
Feedback timeline
Discover current approach to belief in treatment to progression in 1L
Driving dimension: Belief in treatment to progression in 1L
Impact context
An emerging voice with growing visibility. Lighter-touch engagement; identify areas of scientific curiosity and build foundational rapport.
Knowledge context
Limited evidence exposure in this area. Lead with core clinical data and foundational context, keeping it clear and grounded in patient relevance. Let their questions set the pace for going deeper.
Suggested materials
- DESTINY-Breast09 (D967UC00001) Fam-Trastuzumab Deruxtecan-nxki (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-Positive First Line Metastatic Breast Cancer (Reactive Slide Deck; MED-US-TRAS-00436): Slides 8, 16–37
- Discussion Guide: T-DXd+ P in 1L HER2-Positive mBC (Reactive Slide Deck; MED-US-TRAS-00412): Slides 4–8
- DESTINY-Breast09 Medical Q&A (FAQ Document; MED-US-TRAS-00437): All questions from DESTINY-Breast09 Efficacy Results
Feedback timeline
Discover current approach to AE management & prophylaxis
Driving dimension: AE management & prophylaxis
Impact context
An emerging voice with growing visibility. Lighter-touch engagement; identify areas of scientific curiosity and build foundational rapport.
Knowledge context
Limited evidence exposure in this area. Lead with core clinical data and foundational context, keeping it clear and grounded in patient relevance. Let their questions set the pace for going deeper.
Suggested materials
- DESTINY-Breast09 Medical Q&A (FAQ Document; MED-US-TRAS-00437): Question 5 from DESTINY-Breast09 Safety Results
- T-DXd ILD/Pneumonitis Medical Reactive Q&A (FAQ Document; MED-US-TDXD-00018): Questions 39, 61, 87 from T-DXd ILD/Pneumonitis Management Guidelines
- Interstitial Lung Disease (ILD)/Pneumonitis as an Important Identified Risk for Patients Treated With Trastuzumab Deruxtecan (T-DXd) (Reactive Slide Deck; MED-US-TDXD-00047): Slides 31–43, 63–69